Alpha Thalassemia Trait Management

Introduction to Alpha Thalassemia Trait

• Patients with alpha thalassemia trait are asymptomatic and have a normal life expectancy, requiring no treatment, monitoring, or follow-up, and should only receive genetic counseling, according to the American College of Medical Genetics and Genomics 1

Key Management Considerations

• No routine monitoring or follow-up is necessary for patients with alpha thalassemia trait, and annual complete blood counts are unnecessary unless clinically indicated for other reasons, as recommended by the American Academy of Pediatrics 1
• Cardiac monitoring, iron overload assessment, and chelation therapy are not required for thalassemia trait, as stated by the American College of Cardiology 1
• Iron chelation with deferoxamine or deferasirox is reserved exclusively for iron-overloaded patients with dyserythropoietic syndromes requiring chronic transfusions, according to the European Association for the Study of the Liver 2